文献速递消化道肿瘤与早癌消化内镜

追加内镜下切除可能足以治疗早期胃癌内镜切除后侧切缘阳性患者

Additive endoscopic resection may be sufficient for patients with a positive lateral margin after endoscopic resection of early gastric cancer.
PubMed 文献 · Gastrointest Endosc · 2017-03-10

针对早期胃癌内镜切除后仅侧切缘阳性(LM+)的非治愈性切除患者,回顾性分析76例(占2065例的3.6%),其中28例追加胃切除术、25例氩离子凝固术(APC)、23例重复内镜切除(re-ER);追加手术或re-ER后70.6%存在残留癌细胞,但追加手术者均无淋巴结转移;作者认为内镜治疗可能足以作为追加治疗,但re-ER优于APC。

要点

  • 早期胃癌内镜切除后仅侧切缘阳性者,追加内镜治疗可能足够。
  • 追加手术或重复内镜切除后70.6%检出残留癌细胞,但追加手术者无淋巴结转移。
  • 未分化型较分化型更常见残留癌细胞(P = .02),作者认为重复内镜切除优于氩离子凝固术。

核心结论

  • 作者认为,无论采用绝对或扩大内镜切除标准,内镜治疗可能足以作为早期胃癌内镜切除后仅侧切缘阳性患者的追加治疗。
  • 由于不能保证完全消融残留细胞,重复内镜切除是优于氩离子凝固术的追加治疗。

研究设计与样本

  • 回顾性分析2065例接受内镜切除的早期胃癌患者,其中76例(3.6%)为非治愈性切除后仅侧切缘阳性。
  • 76例中28例追加胃切除术、25例追加氩离子凝固术、23例追加重复内镜切除,比较各组临床病理特征。

主要发现

  • 76例中28例(36.8%)符合内镜切除绝对标准,48例(63.2%)符合扩大标准。
  • 扩大标准组追加手术比例为75.0%,高于绝对标准组(P = .014)。
  • 追加手术或重复内镜切除后70.6%的患者观察到残留癌细胞。
  • 未分化型早期胃癌残留癌细胞显著多于分化型(P = .02)。
  • 追加手术患者中均未观察到淋巴结转移。

临床怎么用

  • 作者认为,早期胃癌内镜切除后仅侧切缘阳性者,内镜治疗可能足以作为追加治疗。
  • 作者认为,重复内镜切除是优于氩离子凝固术的追加治疗。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: No well-established treatment strategies exist for lateral margin positivity (LM+) alone after endoscopic resection (ER) of early gastric cancer (EGC). Thus, we aimed to clarify a treatment strategy for non-curative resection (non-CR) with LM+ alone after ER in EGC. METHODS: Among 2065 patients with EGC treated by ER, 76 (3.6%) with only LM+ after non-CR of EGC were reviewed retrospectively. Of these, 28 underwent gastrectomy, 25 underwent argon plasma coagulation (APC), and 23 underwent repeat ER (re-ER). We analyzed the clinicopathologic characteristics of all patients and compared those who underwent additive surgery, APC, or re-ER. RESULTS: Of the 76 patients, 28 (36.8%) fulfilled the absolute criteria and 48 (63.2%) the expanded criteria for ER. Among the latter patients, the proportion undergoing additive surgery was 75.0%, higher than that of patients in the former group (P = .014). Residual cancer cells were observed in 70.6% of patients after additive surgery or re-ER. Residual cancer cells were observed significantly more often in patients with undifferentiated-type than in those with differentiated-type EGC (P = .02). However, no lymph node metastasis was observed in any patient after additive surgery. CONCLUSIONS: Our results suggest that endoscopic treatment may be a sufficient additive therapy for patients with LM+ alone after ER, irrespective of whether the absolute or expanded ER criteria are used. However, as complete ablation of remnant cells cannot be guaranteed, re-ER is a better additive treatment than APC.

来源:Gastrointest Endosc,查看原文。版权归原作者所有。

引用

  1. Kim HW, Kim JH, Park JC, et al. Additive endoscopic resection may be sufficient for patients with a positive lateral margin after endoscopic resection of early gastric cancer. Gastrointest Endosc. 2017. PMID: 28288840. doi:10.1016/j.gie.2017.02.037

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。